Science and Innovation for Effective and Sustainable Healthcare

Submitted by francesca.forzan on Lun, 13/11/2023 - 15:11
Array ( [body] => Array ( [#theme] => field [#weight] => 0 [#title] => Body [#access] => 1 [#label_display] => hidden [#view_mode] => teaser [#language] => und [#field_name] => body [#field_type] => text_with_summary [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 447239 [uid] => 2032 [title] => Science and Innovation for Effective and Sustainable Healthcare [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 105360 [type] => box_lancio_news [language] => it [created] => 1699884683 [changed] => 1706019139 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1706019139 [revision_uid] => 102 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Held in the Aula Magna of Palazzo del Bo, the University of Padua hosts the "Science and Innovation for Effective and Sustainable Healthcare" event on Monday, 20 November. Welcoming representatives from several Italian institutions, members of the National Center for Gene Therapy and Drugs based on RNA Technology, and distinguished scholars, the event also brings the participation of the Italian Minister of University and Research, Anna Maria Bernini.

Focused on the development of gene therapy and drug treatments through RNA technology, the National Center organizes the event as an opportunity to discuss and share an in-depth analysis of the issues related to its activities as it responds to some of the most urgent and complex medical challenges of today.

With welcoming remarks from the University of Padua Rector Daniela Mapelli and Mayor of Padua Sergio Giordani, the event includes talks by Prof Rosario Rizzuto, Prof Giorgio Palù, Dr. Franco Locatelli and Prof Angela Zampella. 

As a University of Padua professor, Rosario Rizzuto is also the President of the National Center for Gene Therapy and Drugs based on RNA Technology. Giorgio Palù is the President of the Italian Medicines Agency and Emeritus professor at the University of Padua. A Director at the Ospedale Pediatrico Bambino Gesù (IRCCS) Dr. Franco Locatelli is also the President of Italy’s Higher Health Council (CSS) and Vice-Chairman of the National Center for Gene Therapy and Drugs based on RNA Technology. Prof Angela Zampella is the Director of the Department of Pharmacy at the University of Naples Federico II and the Supervisory Board President of the National Center for Gene Therapy and Drugs based on RNA Technology.

Followed with a round table moderated by Luigi Ripamonti, journalist and editor-in-chief of Corriere Salute and the Health section of the Corriere della Sera website.

The full programme and link to the livestreaming event is available at  https://www.rna-genetherapy.eu.

The National Center brings together 46 public and private research Italian institutions and companies to assemble a network of experts across different disciplines such as molecular biology, genetics, biotechnology, and clinical medicine.

Composed of 10 Spokes, the National Center acts as the Hub focused on innovative energies within different but related projects. By creating cutting-edge infrastructures and laboratories, the Center encourages entrepreneurial initiatives with high technological content to enhance the results of scientific and clinical research.

Focused on making healthcare effective and sustainable, the National Center aims to translate research results into concrete clinical application through the development of personalized medicines.  By working together, the first object of the National Center is improving the lives of those suffering from genetic diseases.

[summary] => [format] => 2 [safe_value] =>

Held in the Aula Magna of Palazzo del Bo, the University of Padua hosts the "Science and Innovation for Effective and Sustainable Healthcare" event on Monday, 20 November. Welcoming representatives from several Italian institutions, members of the National Center for Gene Therapy and Drugs based on RNA Technology, and distinguished scholars, the event also brings the participation of the Italian Minister of University and Research, Anna Maria Bernini.

Focused on the development of gene therapy and drug treatments through RNA technology, the National Center organizes the event as an opportunity to discuss and share an in-depth analysis of the issues related to its activities as it responds to some of the most urgent and complex medical challenges of today.

With welcoming remarks from the University of Padua Rector Daniela Mapelli and Mayor of Padua Sergio Giordani, the event includes talks by Prof Rosario Rizzuto, Prof Giorgio Palù, Dr. Franco Locatelli and Prof Angela Zampella. 

As a University of Padua professor, Rosario Rizzuto is also the President of the National Center for Gene Therapy and Drugs based on RNA Technology. Giorgio Palù is the President of the Italian Medicines Agency and Emeritus professor at the University of Padua. A Director at the Ospedale Pediatrico Bambino Gesù (IRCCS) Dr. Franco Locatelli is also the President of Italy’s Higher Health Council (CSS) and Vice-Chairman of the National Center for Gene Therapy and Drugs based on RNA Technology. Prof Angela Zampella is the Director of the Department of Pharmacy at the University of Naples Federico II and the Supervisory Board President of the National Center for Gene Therapy and Drugs based on RNA Technology.

Followed with a round table moderated by Luigi Ripamonti, journalist and editor-in-chief of Corriere Salute and the Health section of the Corriere della Sera website.

The full programme and link to the livestreaming event is available at  https://www.rna-genetherapy.eu.

The National Center brings together 46 public and private research Italian institutions and companies to assemble a network of experts across different disciplines such as molecular biology, genetics, biotechnology, and clinical medicine.

Composed of 10 Spokes, the National Center acts as the Hub focused on innovative energies within different but related projects. By creating cutting-edge infrastructures and laboratories, the Center encourages entrepreneurial initiatives with high technological content to enhance the results of scientific and clinical research.

Focused on making healthcare effective and sustainable, the National Center aims to translate research results into concrete clinical application through the development of personalized medicines.  By working together, the first object of the National Center is improving the lives of those suffering from genetic diseases.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-11-13T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 124772 [uid] => 2032 [filename] => RNA Genetherapy_declinazioni_carosello 653x430.png [uri] => public://RNA Genetherapy_declinazioni_carosello 653x430_0.png [filemime] => image/png [filesize] => 427395 [status] => 1 [timestamp] => 1699884683 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 430 [width] => 653 ) [height] => 430 [width] => 653 [alt] => dna [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => On Monday, 20 November the Aula Magna of Palazzo del Bo hosts the event "Science and Innovation for Effective and Sustainable Healthcare" organized by the National Center for Gene Therapy and Drugs based on RNA Technology [format] => [safe_value] => On Monday, 20 November the Aula Magna of Palazzo del Bo hosts the event "Science and Innovation for Effective and Sustainable Healthcare" organized by the National Center for Gene Therapy and Drugs based on RNA Technology ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2261 ) [1] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-11-13T00:00:00 [value2] => 2023-11-22T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 5 [current_revision_id] => 447239 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] =>

Held in the Aula Magna of Palazzo del Bo, the University of Padua hosts the "Science and Innovation for Effective and Sustainable Healthcare" event on Monday, 20 November. Welcoming representatives from several Italian institutions, members of the National Center for Gene Therapy and Drugs based on RNA Technology, and distinguished scholars, the event also brings the participation of the Italian Minister of University and Research, Anna Maria Bernini.

Focused on the development of gene therapy and drug treatments through RNA technology, the National Center organizes the event as an opportunity to discuss and share an in-depth analysis of the issues related to its activities as it responds to some of the most urgent and complex medical challenges of today.

With welcoming remarks from the University of Padua Rector Daniela Mapelli and Mayor of Padua Sergio Giordani, the event includes talks by Prof Rosario Rizzuto, Prof Giorgio Palù, Dr. Franco Locatelli and Prof Angela Zampella. 

As a University of Padua professor, Rosario Rizzuto is also the President of the National Center for Gene Therapy and Drugs based on RNA Technology. Giorgio Palù is the President of the Italian Medicines Agency and Emeritus professor at the University of Padua. A Director at the Ospedale Pediatrico Bambino Gesù (IRCCS) Dr. Franco Locatelli is also the President of Italy’s Higher Health Council (CSS) and Vice-Chairman of the National Center for Gene Therapy and Drugs based on RNA Technology. Prof Angela Zampella is the Director of the Department of Pharmacy at the University of Naples Federico II and the Supervisory Board President of the National Center for Gene Therapy and Drugs based on RNA Technology.

Followed with a round table moderated by Luigi Ripamonti, journalist and editor-in-chief of Corriere Salute and the Health section of the Corriere della Sera website.

The full programme and link to the livestreaming event is available at  https://www.rna-genetherapy.eu.

The National Center brings together 46 public and private research Italian institutions and companies to assemble a network of experts across different disciplines such as molecular biology, genetics, biotechnology, and clinical medicine.

Composed of 10 Spokes, the National Center acts as the Hub focused on innovative energies within different but related projects. By creating cutting-edge infrastructures and laboratories, the Center encourages entrepreneurial initiatives with high technological content to enhance the results of scientific and clinical research.

Focused on making healthcare effective and sustainable, the National Center aims to translate research results into concrete clinical application through the development of personalized medicines.  By working together, the first object of the National Center is improving the lives of those suffering from genetic diseases.

[summary] => [format] => 2 [safe_value] =>

Held in the Aula Magna of Palazzo del Bo, the University of Padua hosts the "Science and Innovation for Effective and Sustainable Healthcare" event on Monday, 20 November. Welcoming representatives from several Italian institutions, members of the National Center for Gene Therapy and Drugs based on RNA Technology, and distinguished scholars, the event also brings the participation of the Italian Minister of University and Research, Anna Maria Bernini.

Focused on the development of gene therapy and drug treatments through RNA technology, the National Center organizes the event as an opportunity to discuss and share an in-depth analysis of the issues related to its activities as it responds to some of the most urgent and complex medical challenges of today.

With welcoming remarks from the University of Padua Rector Daniela Mapelli and Mayor of Padua Sergio Giordani, the event includes talks by Prof Rosario Rizzuto, Prof Giorgio Palù, Dr. Franco Locatelli and Prof Angela Zampella. 

As a University of Padua professor, Rosario Rizzuto is also the President of the National Center for Gene Therapy and Drugs based on RNA Technology. Giorgio Palù is the President of the Italian Medicines Agency and Emeritus professor at the University of Padua. A Director at the Ospedale Pediatrico Bambino Gesù (IRCCS) Dr. Franco Locatelli is also the President of Italy’s Higher Health Council (CSS) and Vice-Chairman of the National Center for Gene Therapy and Drugs based on RNA Technology. Prof Angela Zampella is the Director of the Department of Pharmacy at the University of Naples Federico II and the Supervisory Board President of the National Center for Gene Therapy and Drugs based on RNA Technology.

Followed with a round table moderated by Luigi Ripamonti, journalist and editor-in-chief of Corriere Salute and the Health section of the Corriere della Sera website.

The full programme and link to the livestreaming event is available at  https://www.rna-genetherapy.eu.

The National Center brings together 46 public and private research Italian institutions and companies to assemble a network of experts across different disciplines such as molecular biology, genetics, biotechnology, and clinical medicine.

Composed of 10 Spokes, the National Center acts as the Hub focused on innovative energies within different but related projects. By creating cutting-edge infrastructures and laboratories, the Center encourages entrepreneurial initiatives with high technological content to enhance the results of scientific and clinical research.

Focused on making healthcare effective and sustainable, the National Center aims to translate research results into concrete clinical application through the development of personalized medicines.  By working together, the first object of the National Center is improving the lives of those suffering from genetic diseases.

[safe_summary] => ) ) [#formatter] => text_summary_or_trimmed [0] => Array ( [#markup] =>

Held in the Aula Magna of Palazzo del Bo, the University of Padua hosts the "Science and Innovation for Effective and Sustainable Healthcare" event on Monday, 20 November. Welcoming representatives from several Italian institutions, members of the National Center for Gene Therapy and Drugs based on RNA Technology, and distinguished scholars, the event also brings the participation of the Italian Minister of University and Research, Anna Maria Bernini.

) ) [field_img_box_lancio_news] => Array ( [#theme] => field [#weight] => 0 [#title] => Immagine [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_img_box_lancio_news [#field_type] => image [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 447239 [uid] => 2032 [title] => Science and Innovation for Effective and Sustainable Healthcare [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 105360 [type] => box_lancio_news [language] => it [created] => 1699884683 [changed] => 1706019139 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1706019139 [revision_uid] => 102 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Held in the Aula Magna of Palazzo del Bo, the University of Padua hosts the "Science and Innovation for Effective and Sustainable Healthcare" event on Monday, 20 November. Welcoming representatives from several Italian institutions, members of the National Center for Gene Therapy and Drugs based on RNA Technology, and distinguished scholars, the event also brings the participation of the Italian Minister of University and Research, Anna Maria Bernini.

Focused on the development of gene therapy and drug treatments through RNA technology, the National Center organizes the event as an opportunity to discuss and share an in-depth analysis of the issues related to its activities as it responds to some of the most urgent and complex medical challenges of today.

With welcoming remarks from the University of Padua Rector Daniela Mapelli and Mayor of Padua Sergio Giordani, the event includes talks by Prof Rosario Rizzuto, Prof Giorgio Palù, Dr. Franco Locatelli and Prof Angela Zampella. 

As a University of Padua professor, Rosario Rizzuto is also the President of the National Center for Gene Therapy and Drugs based on RNA Technology. Giorgio Palù is the President of the Italian Medicines Agency and Emeritus professor at the University of Padua. A Director at the Ospedale Pediatrico Bambino Gesù (IRCCS) Dr. Franco Locatelli is also the President of Italy’s Higher Health Council (CSS) and Vice-Chairman of the National Center for Gene Therapy and Drugs based on RNA Technology. Prof Angela Zampella is the Director of the Department of Pharmacy at the University of Naples Federico II and the Supervisory Board President of the National Center for Gene Therapy and Drugs based on RNA Technology.

Followed with a round table moderated by Luigi Ripamonti, journalist and editor-in-chief of Corriere Salute and the Health section of the Corriere della Sera website.

The full programme and link to the livestreaming event is available at  https://www.rna-genetherapy.eu.

The National Center brings together 46 public and private research Italian institutions and companies to assemble a network of experts across different disciplines such as molecular biology, genetics, biotechnology, and clinical medicine.

Composed of 10 Spokes, the National Center acts as the Hub focused on innovative energies within different but related projects. By creating cutting-edge infrastructures and laboratories, the Center encourages entrepreneurial initiatives with high technological content to enhance the results of scientific and clinical research.

Focused on making healthcare effective and sustainable, the National Center aims to translate research results into concrete clinical application through the development of personalized medicines.  By working together, the first object of the National Center is improving the lives of those suffering from genetic diseases.

[summary] => [format] => 2 [safe_value] =>

Held in the Aula Magna of Palazzo del Bo, the University of Padua hosts the "Science and Innovation for Effective and Sustainable Healthcare" event on Monday, 20 November. Welcoming representatives from several Italian institutions, members of the National Center for Gene Therapy and Drugs based on RNA Technology, and distinguished scholars, the event also brings the participation of the Italian Minister of University and Research, Anna Maria Bernini.

Focused on the development of gene therapy and drug treatments through RNA technology, the National Center organizes the event as an opportunity to discuss and share an in-depth analysis of the issues related to its activities as it responds to some of the most urgent and complex medical challenges of today.

With welcoming remarks from the University of Padua Rector Daniela Mapelli and Mayor of Padua Sergio Giordani, the event includes talks by Prof Rosario Rizzuto, Prof Giorgio Palù, Dr. Franco Locatelli and Prof Angela Zampella. 

As a University of Padua professor, Rosario Rizzuto is also the President of the National Center for Gene Therapy and Drugs based on RNA Technology. Giorgio Palù is the President of the Italian Medicines Agency and Emeritus professor at the University of Padua. A Director at the Ospedale Pediatrico Bambino Gesù (IRCCS) Dr. Franco Locatelli is also the President of Italy’s Higher Health Council (CSS) and Vice-Chairman of the National Center for Gene Therapy and Drugs based on RNA Technology. Prof Angela Zampella is the Director of the Department of Pharmacy at the University of Naples Federico II and the Supervisory Board President of the National Center for Gene Therapy and Drugs based on RNA Technology.

Followed with a round table moderated by Luigi Ripamonti, journalist and editor-in-chief of Corriere Salute and the Health section of the Corriere della Sera website.

The full programme and link to the livestreaming event is available at  https://www.rna-genetherapy.eu.

The National Center brings together 46 public and private research Italian institutions and companies to assemble a network of experts across different disciplines such as molecular biology, genetics, biotechnology, and clinical medicine.

Composed of 10 Spokes, the National Center acts as the Hub focused on innovative energies within different but related projects. By creating cutting-edge infrastructures and laboratories, the Center encourages entrepreneurial initiatives with high technological content to enhance the results of scientific and clinical research.

Focused on making healthcare effective and sustainable, the National Center aims to translate research results into concrete clinical application through the development of personalized medicines.  By working together, the first object of the National Center is improving the lives of those suffering from genetic diseases.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-11-13T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 124772 [uid] => 2032 [filename] => RNA Genetherapy_declinazioni_carosello 653x430.png [uri] => public://RNA Genetherapy_declinazioni_carosello 653x430_0.png [filemime] => image/png [filesize] => 427395 [status] => 1 [timestamp] => 1699884683 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 430 [width] => 653 ) [height] => 430 [width] => 653 [alt] => dna [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => On Monday, 20 November the Aula Magna of Palazzo del Bo hosts the event "Science and Innovation for Effective and Sustainable Healthcare" organized by the National Center for Gene Therapy and Drugs based on RNA Technology [format] => [safe_value] => On Monday, 20 November the Aula Magna of Palazzo del Bo hosts the event "Science and Innovation for Effective and Sustainable Healthcare" organized by the National Center for Gene Therapy and Drugs based on RNA Technology ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2261 ) [1] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-11-13T00:00:00 [value2] => 2023-11-22T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 5 [current_revision_id] => 447239 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 124772 [uid] => 2032 [filename] => RNA Genetherapy_declinazioni_carosello 653x430.png [uri] => public://RNA Genetherapy_declinazioni_carosello 653x430_0.png [filemime] => image/png [filesize] => 427395 [status] => 1 [timestamp] => 1699884683 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 430 [width] => 653 ) [height] => 430 [width] => 653 [alt] => dna [title] => ) ) [#formatter] => image [0] => Array ( [#theme] => image_formatter [#item] => Array ( [fid] => 124772 [uid] => 2032 [filename] => RNA Genetherapy_declinazioni_carosello 653x430.png [uri] => public://RNA Genetherapy_declinazioni_carosello 653x430_0.png [filemime] => image/png [filesize] => 427395 [status] => 1 [timestamp] => 1699884683 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 430 [width] => 653 ) [height] => 430 [width] => 653 [alt] => dna [title] => ) [#image_style] => [#path] => ) ) [field_abstract_news] => Array ( [#theme] => field [#weight] => 0 [#title] => Abstract [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_abstract_news [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 447239 [uid] => 2032 [title] => Science and Innovation for Effective and Sustainable Healthcare [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 105360 [type] => box_lancio_news [language] => it [created] => 1699884683 [changed] => 1706019139 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1706019139 [revision_uid] => 102 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Held in the Aula Magna of Palazzo del Bo, the University of Padua hosts the "Science and Innovation for Effective and Sustainable Healthcare" event on Monday, 20 November. Welcoming representatives from several Italian institutions, members of the National Center for Gene Therapy and Drugs based on RNA Technology, and distinguished scholars, the event also brings the participation of the Italian Minister of University and Research, Anna Maria Bernini.

Focused on the development of gene therapy and drug treatments through RNA technology, the National Center organizes the event as an opportunity to discuss and share an in-depth analysis of the issues related to its activities as it responds to some of the most urgent and complex medical challenges of today.

With welcoming remarks from the University of Padua Rector Daniela Mapelli and Mayor of Padua Sergio Giordani, the event includes talks by Prof Rosario Rizzuto, Prof Giorgio Palù, Dr. Franco Locatelli and Prof Angela Zampella. 

As a University of Padua professor, Rosario Rizzuto is also the President of the National Center for Gene Therapy and Drugs based on RNA Technology. Giorgio Palù is the President of the Italian Medicines Agency and Emeritus professor at the University of Padua. A Director at the Ospedale Pediatrico Bambino Gesù (IRCCS) Dr. Franco Locatelli is also the President of Italy’s Higher Health Council (CSS) and Vice-Chairman of the National Center for Gene Therapy and Drugs based on RNA Technology. Prof Angela Zampella is the Director of the Department of Pharmacy at the University of Naples Federico II and the Supervisory Board President of the National Center for Gene Therapy and Drugs based on RNA Technology.

Followed with a round table moderated by Luigi Ripamonti, journalist and editor-in-chief of Corriere Salute and the Health section of the Corriere della Sera website.

The full programme and link to the livestreaming event is available at  https://www.rna-genetherapy.eu.

The National Center brings together 46 public and private research Italian institutions and companies to assemble a network of experts across different disciplines such as molecular biology, genetics, biotechnology, and clinical medicine.

Composed of 10 Spokes, the National Center acts as the Hub focused on innovative energies within different but related projects. By creating cutting-edge infrastructures and laboratories, the Center encourages entrepreneurial initiatives with high technological content to enhance the results of scientific and clinical research.

Focused on making healthcare effective and sustainable, the National Center aims to translate research results into concrete clinical application through the development of personalized medicines.  By working together, the first object of the National Center is improving the lives of those suffering from genetic diseases.

[summary] => [format] => 2 [safe_value] =>

Held in the Aula Magna of Palazzo del Bo, the University of Padua hosts the "Science and Innovation for Effective and Sustainable Healthcare" event on Monday, 20 November. Welcoming representatives from several Italian institutions, members of the National Center for Gene Therapy and Drugs based on RNA Technology, and distinguished scholars, the event also brings the participation of the Italian Minister of University and Research, Anna Maria Bernini.

Focused on the development of gene therapy and drug treatments through RNA technology, the National Center organizes the event as an opportunity to discuss and share an in-depth analysis of the issues related to its activities as it responds to some of the most urgent and complex medical challenges of today.

With welcoming remarks from the University of Padua Rector Daniela Mapelli and Mayor of Padua Sergio Giordani, the event includes talks by Prof Rosario Rizzuto, Prof Giorgio Palù, Dr. Franco Locatelli and Prof Angela Zampella. 

As a University of Padua professor, Rosario Rizzuto is also the President of the National Center for Gene Therapy and Drugs based on RNA Technology. Giorgio Palù is the President of the Italian Medicines Agency and Emeritus professor at the University of Padua. A Director at the Ospedale Pediatrico Bambino Gesù (IRCCS) Dr. Franco Locatelli is also the President of Italy’s Higher Health Council (CSS) and Vice-Chairman of the National Center for Gene Therapy and Drugs based on RNA Technology. Prof Angela Zampella is the Director of the Department of Pharmacy at the University of Naples Federico II and the Supervisory Board President of the National Center for Gene Therapy and Drugs based on RNA Technology.

Followed with a round table moderated by Luigi Ripamonti, journalist and editor-in-chief of Corriere Salute and the Health section of the Corriere della Sera website.

The full programme and link to the livestreaming event is available at  https://www.rna-genetherapy.eu.

The National Center brings together 46 public and private research Italian institutions and companies to assemble a network of experts across different disciplines such as molecular biology, genetics, biotechnology, and clinical medicine.

Composed of 10 Spokes, the National Center acts as the Hub focused on innovative energies within different but related projects. By creating cutting-edge infrastructures and laboratories, the Center encourages entrepreneurial initiatives with high technological content to enhance the results of scientific and clinical research.

Focused on making healthcare effective and sustainable, the National Center aims to translate research results into concrete clinical application through the development of personalized medicines.  By working together, the first object of the National Center is improving the lives of those suffering from genetic diseases.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-11-13T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 124772 [uid] => 2032 [filename] => RNA Genetherapy_declinazioni_carosello 653x430.png [uri] => public://RNA Genetherapy_declinazioni_carosello 653x430_0.png [filemime] => image/png [filesize] => 427395 [status] => 1 [timestamp] => 1699884683 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 430 [width] => 653 ) [height] => 430 [width] => 653 [alt] => dna [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => On Monday, 20 November the Aula Magna of Palazzo del Bo hosts the event "Science and Innovation for Effective and Sustainable Healthcare" organized by the National Center for Gene Therapy and Drugs based on RNA Technology [format] => [safe_value] => On Monday, 20 November the Aula Magna of Palazzo del Bo hosts the event "Science and Innovation for Effective and Sustainable Healthcare" organized by the National Center for Gene Therapy and Drugs based on RNA Technology ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2261 ) [1] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-11-13T00:00:00 [value2] => 2023-11-22T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 5 [current_revision_id] => 447239 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => On Monday, 20 November the Aula Magna of Palazzo del Bo hosts the event "Science and Innovation for Effective and Sustainable Healthcare" organized by the National Center for Gene Therapy and Drugs based on RNA Technology [format] => [safe_value] => On Monday, 20 November the Aula Magna of Palazzo del Bo hosts the event "Science and Innovation for Effective and Sustainable Healthcare" organized by the National Center for Gene Therapy and Drugs based on RNA Technology ) ) [#formatter] => text_default [0] => Array ( [#markup] => On Monday, 20 November the Aula Magna of Palazzo del Bo hosts the event "Science and Innovation for Effective and Sustainable Healthcare" organized by the National Center for Gene Therapy and Drugs based on RNA Technology ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about Science and Innovation for Effective and Sustainable Healthcare [href] => node/105360 [html] => 1 [attributes] => Array ( [rel] => tag [title] => Science and Innovation for Effective and Sustainable Healthcare ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) [field_date_box_lancio_news] => Array ( [#theme] => field [#weight] => 1 [#title] => Data [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_date_box_lancio_news [#field_type] => date [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 447239 [uid] => 2032 [title] => Science and Innovation for Effective and Sustainable Healthcare [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 105360 [type] => box_lancio_news [language] => it [created] => 1699884683 [changed] => 1706019139 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1706019139 [revision_uid] => 102 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Held in the Aula Magna of Palazzo del Bo, the University of Padua hosts the "Science and Innovation for Effective and Sustainable Healthcare" event on Monday, 20 November. Welcoming representatives from several Italian institutions, members of the National Center for Gene Therapy and Drugs based on RNA Technology, and distinguished scholars, the event also brings the participation of the Italian Minister of University and Research, Anna Maria Bernini.

Focused on the development of gene therapy and drug treatments through RNA technology, the National Center organizes the event as an opportunity to discuss and share an in-depth analysis of the issues related to its activities as it responds to some of the most urgent and complex medical challenges of today.

With welcoming remarks from the University of Padua Rector Daniela Mapelli and Mayor of Padua Sergio Giordani, the event includes talks by Prof Rosario Rizzuto, Prof Giorgio Palù, Dr. Franco Locatelli and Prof Angela Zampella. 

As a University of Padua professor, Rosario Rizzuto is also the President of the National Center for Gene Therapy and Drugs based on RNA Technology. Giorgio Palù is the President of the Italian Medicines Agency and Emeritus professor at the University of Padua. A Director at the Ospedale Pediatrico Bambino Gesù (IRCCS) Dr. Franco Locatelli is also the President of Italy’s Higher Health Council (CSS) and Vice-Chairman of the National Center for Gene Therapy and Drugs based on RNA Technology. Prof Angela Zampella is the Director of the Department of Pharmacy at the University of Naples Federico II and the Supervisory Board President of the National Center for Gene Therapy and Drugs based on RNA Technology.

Followed with a round table moderated by Luigi Ripamonti, journalist and editor-in-chief of Corriere Salute and the Health section of the Corriere della Sera website.

The full programme and link to the livestreaming event is available at  https://www.rna-genetherapy.eu.

The National Center brings together 46 public and private research Italian institutions and companies to assemble a network of experts across different disciplines such as molecular biology, genetics, biotechnology, and clinical medicine.

Composed of 10 Spokes, the National Center acts as the Hub focused on innovative energies within different but related projects. By creating cutting-edge infrastructures and laboratories, the Center encourages entrepreneurial initiatives with high technological content to enhance the results of scientific and clinical research.

Focused on making healthcare effective and sustainable, the National Center aims to translate research results into concrete clinical application through the development of personalized medicines.  By working together, the first object of the National Center is improving the lives of those suffering from genetic diseases.

[summary] => [format] => 2 [safe_value] =>

Held in the Aula Magna of Palazzo del Bo, the University of Padua hosts the "Science and Innovation for Effective and Sustainable Healthcare" event on Monday, 20 November. Welcoming representatives from several Italian institutions, members of the National Center for Gene Therapy and Drugs based on RNA Technology, and distinguished scholars, the event also brings the participation of the Italian Minister of University and Research, Anna Maria Bernini.

Focused on the development of gene therapy and drug treatments through RNA technology, the National Center organizes the event as an opportunity to discuss and share an in-depth analysis of the issues related to its activities as it responds to some of the most urgent and complex medical challenges of today.

With welcoming remarks from the University of Padua Rector Daniela Mapelli and Mayor of Padua Sergio Giordani, the event includes talks by Prof Rosario Rizzuto, Prof Giorgio Palù, Dr. Franco Locatelli and Prof Angela Zampella. 

As a University of Padua professor, Rosario Rizzuto is also the President of the National Center for Gene Therapy and Drugs based on RNA Technology. Giorgio Palù is the President of the Italian Medicines Agency and Emeritus professor at the University of Padua. A Director at the Ospedale Pediatrico Bambino Gesù (IRCCS) Dr. Franco Locatelli is also the President of Italy’s Higher Health Council (CSS) and Vice-Chairman of the National Center for Gene Therapy and Drugs based on RNA Technology. Prof Angela Zampella is the Director of the Department of Pharmacy at the University of Naples Federico II and the Supervisory Board President of the National Center for Gene Therapy and Drugs based on RNA Technology.

Followed with a round table moderated by Luigi Ripamonti, journalist and editor-in-chief of Corriere Salute and the Health section of the Corriere della Sera website.

The full programme and link to the livestreaming event is available at  https://www.rna-genetherapy.eu.

The National Center brings together 46 public and private research Italian institutions and companies to assemble a network of experts across different disciplines such as molecular biology, genetics, biotechnology, and clinical medicine.

Composed of 10 Spokes, the National Center acts as the Hub focused on innovative energies within different but related projects. By creating cutting-edge infrastructures and laboratories, the Center encourages entrepreneurial initiatives with high technological content to enhance the results of scientific and clinical research.

Focused on making healthcare effective and sustainable, the National Center aims to translate research results into concrete clinical application through the development of personalized medicines.  By working together, the first object of the National Center is improving the lives of those suffering from genetic diseases.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-11-13T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 124772 [uid] => 2032 [filename] => RNA Genetherapy_declinazioni_carosello 653x430.png [uri] => public://RNA Genetherapy_declinazioni_carosello 653x430_0.png [filemime] => image/png [filesize] => 427395 [status] => 1 [timestamp] => 1699884683 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 430 [width] => 653 ) [height] => 430 [width] => 653 [alt] => dna [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => On Monday, 20 November the Aula Magna of Palazzo del Bo hosts the event "Science and Innovation for Effective and Sustainable Healthcare" organized by the National Center for Gene Therapy and Drugs based on RNA Technology [format] => [safe_value] => On Monday, 20 November the Aula Magna of Palazzo del Bo hosts the event "Science and Innovation for Effective and Sustainable Healthcare" organized by the National Center for Gene Therapy and Drugs based on RNA Technology ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2261 ) [1] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-11-13T00:00:00 [value2] => 2023-11-22T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 1 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 5 [current_revision_id] => 447239 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => 2023-11-13T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) [#formatter] => date_default [0] => Array ( [#markup] => Lun, 13/11/2023 ) ) )

2023N53 - Comunicazione calendario e sedi prove d'esame

Submitted by stefano.zampieri on Lun, 13/11/2023 - 14:38
Array ( [field_titolo_frontend_all] => Array ( [#theme] => field [#weight] => -4 [#title] => Titolo frontend [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_titolo_frontend_all [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 441884 [uid] => 32 [title] => 2023N53 - Comunicazione calendario e sedi prove d'esame [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 105359 [type] => allegato [language] => it [created] => 1699882725 [changed] => 1699882725 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1699882725 [revision_uid] => 32 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Comunicazione calendario e sedi prove d'esame [format] => [safe_value] => Comunicazione calendario e sedi prove d'esame ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 124764 [uid] => 32 [filename] => 12 comunicazione calendario e sedi prove d_esame 2023N53 signed.pdf [uri] => public://2023/12 comunicazione calendario e sedi prove d_esame 2023N53 signed.pdf [filemime] => application/pdf [filesize] => 398193 [status] => 1 [timestamp] => 1699882887 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2529 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 441884 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Comunicazione calendario e sedi prove d'esame [format] => [safe_value] => Comunicazione calendario e sedi prove d'esame ) ) [#formatter] => text_default [0] => Array ( [#markup] => Comunicazione calendario e sedi prove d'esame ) ) [field_allegato_file] => Array ( [#theme] => field [#weight] => -3 [#title] => File [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_allegato_file [#field_type] => file [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 441884 [uid] => 32 [title] => 2023N53 - Comunicazione calendario e sedi prove d'esame [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 105359 [type] => allegato [language] => it [created] => 1699882725 [changed] => 1699882725 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1699882725 [revision_uid] => 32 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Comunicazione calendario e sedi prove d'esame [format] => [safe_value] => Comunicazione calendario e sedi prove d'esame ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 124764 [uid] => 32 [filename] => 12 comunicazione calendario e sedi prove d_esame 2023N53 signed.pdf [uri] => public://2023/12 comunicazione calendario e sedi prove d_esame 2023N53 signed.pdf [filemime] => application/pdf [filesize] => 398193 [status] => 1 [timestamp] => 1699882887 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2529 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 441884 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 124764 [uid] => 32 [filename] => 12 comunicazione calendario e sedi prove d_esame 2023N53 signed.pdf [uri] => public://2023/12 comunicazione calendario e sedi prove d_esame 2023N53 signed.pdf [filemime] => application/pdf [filesize] => 398193 [status] => 1 [timestamp] => 1699882887 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2529 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) [#formatter] => file_default [0] => Array ( [#theme] => file_link [#file] => stdClass Object ( [fid] => 124764 [uid] => 32 [filename] => 12 comunicazione calendario e sedi prove d_esame 2023N53 signed.pdf [uri] => public://2023/12 comunicazione calendario e sedi prove d_esame 2023N53 signed.pdf [filemime] => application/pdf [filesize] => 398193 [status] => 1 [timestamp] => 1699882887 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2529 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about 2023N53 - Comunicazione calendario e sedi prove d'esame [href] => node/105359 [html] => 1 [attributes] => Array ( [rel] => tag [title] => 2023N53 - Comunicazione calendario e sedi prove d'esame ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

Research identifies a new way in which Covid-19 enters human cells

Submitted by francesca.forzan on Lun, 13/11/2023 - 13:39
Array ( [body] => Array ( [#theme] => field [#weight] => 0 [#title] => Body [#access] => 1 [#label_display] => hidden [#view_mode] => teaser [#language] => und [#field_name] => body [#field_type] => text_with_summary [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 441879 [uid] => 2032 [title] => Research identifies a new way in which Covid-19 enters human cells [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 105358 [type] => box_lancio_news [language] => it [created] => 1699879199 [changed] => 1699880483 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1699880483 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Published in Cell Press, the study by the University of Padua and Human Technopole, RAGE engagement by SARS-CoV-2 enables monocyte infection and underlies COVID-19 severity identifies how SARS-CoV-2 binds the Receptor for Advanced Glycation Endproducts (the RAGE receptor) and how this interaction drives an innate immune response. The publication is the result of the collaboration between researchers coordinated by Prof. Antonella Viola at the Department of Biomedical Sciences at the University of Padua and researchers from Human Technopole coordinated by Prof. Giuseppe Testa, with the support of the European Institute of Oncology and the University of Milan. The study demonstrates how the RAGE receptor found on the surface of specific human immune cells penetrates them and pathologically alters their function. This study also shows how the involvement of RAGE determines the degree of severity with which COVID-19 can manifest.

The study took data from patients hospitalized for COVID-19 during the first phase of the pandemic at the Complex Operative Unit for Infectious Diseases and Tropical Diseases in Padua, led by Dr Anna Maria Cattelan. The research team in Padua isolated and characterized the immune cells from the blood of COVID-19 patients at three different time points during and after the infection, i.e. on admission, at discharge and one month after release.

The analysis then continued in Milan, where researchers used technologies to analyze what happens inside a single cell by looking at the expression of all 20,000 genes encoded by its DNA. The amount of data observed for each patient is comparable to the amount of information in a 140-megapixel image, a resolution at the frontier of the possibilities of commonly available cameras. Images captured over different points of hospitalization amplified the amount of data and provided insight to each patients’ response to the SARS-CoV-2 virus.

The analysis showed that the RAGE receptor induces specific alterations in gene regulation, enhancing the inflammatory effect of the virus and contributing to disease exacerbation. Identifying this new mode of interaction between the virus and human cells is crucial for developing targeted therapeutic strategies, mainly to protect individuals at risk of severe complications, such as the elderly or frail individuals. This discovery could lay the foundations for a more targeted and effective approach to counteracting the spread of the virus in these vulnerable groups. For instance, by comparing the characteristic molecular responses detected in the study with those collected in some global databases, scientists also found that the drug Baricitinib, already approved by AIFA in 2021 for the treatment of COVID-19, could potentially reverse the identified harmful effects.

[summary] => [format] => 2 [safe_value] =>

Published in Cell Press, the study by the University of Padua and Human Technopole, RAGE engagement by SARS-CoV-2 enables monocyte infection and underlies COVID-19 severity identifies how SARS-CoV-2 binds the Receptor for Advanced Glycation Endproducts (the RAGE receptor) and how this interaction drives an innate immune response. The publication is the result of the collaboration between researchers coordinated by Prof. Antonella Viola at the Department of Biomedical Sciences at the University of Padua and researchers from Human Technopole coordinated by Prof. Giuseppe Testa, with the support of the European Institute of Oncology and the University of Milan. The study demonstrates how the RAGE receptor found on the surface of specific human immune cells penetrates them and pathologically alters their function. This study also shows how the involvement of RAGE determines the degree of severity with which COVID-19 can manifest.

The study took data from patients hospitalized for COVID-19 during the first phase of the pandemic at the Complex Operative Unit for Infectious Diseases and Tropical Diseases in Padua, led by Dr Anna Maria Cattelan. The research team in Padua isolated and characterized the immune cells from the blood of COVID-19 patients at three different time points during and after the infection, i.e. on admission, at discharge and one month after release.

The analysis then continued in Milan, where researchers used technologies to analyze what happens inside a single cell by looking at the expression of all 20,000 genes encoded by its DNA. The amount of data observed for each patient is comparable to the amount of information in a 140-megapixel image, a resolution at the frontier of the possibilities of commonly available cameras. Images captured over different points of hospitalization amplified the amount of data and provided insight to each patients’ response to the SARS-CoV-2 virus.

The analysis showed that the RAGE receptor induces specific alterations in gene regulation, enhancing the inflammatory effect of the virus and contributing to disease exacerbation. Identifying this new mode of interaction between the virus and human cells is crucial for developing targeted therapeutic strategies, mainly to protect individuals at risk of severe complications, such as the elderly or frail individuals. This discovery could lay the foundations for a more targeted and effective approach to counteracting the spread of the virus in these vulnerable groups. For instance, by comparing the characteristic molecular responses detected in the study with those collected in some global databases, scientists also found that the drug Baricitinib, already approved by AIFA in 2021 for the treatment of COVID-19, could potentially reverse the identified harmful effects.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-11-13T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 124758 [uid] => 2032 [filename] => n_covid_mascherinadonna_2.jpg [uri] => public://n_covid_mascherinadonna_2_0.jpg [filemime] => image/jpeg [filesize] => 17377 [status] => 1 [timestamp] => 1699879199 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => mask [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => A new study by the University of Padua and Human Technopole identifies how SARS-CoV-2 binds the Receptor for Advanced Glycation Endproducts (the RAGE receptor) and how this interaction drives an innate immune response [format] => [safe_value] => A new study by the University of Padua and Human Technopole identifies how SARS-CoV-2 binds the Receptor for Advanced Glycation Endproducts (the RAGE receptor) and how this interaction drives an innate immune response ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-11-13T00:00:00 [value2] => 2024-11-13T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 0 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 3 [current_revision_id] => 441879 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] =>

Published in Cell Press, the study by the University of Padua and Human Technopole, RAGE engagement by SARS-CoV-2 enables monocyte infection and underlies COVID-19 severity identifies how SARS-CoV-2 binds the Receptor for Advanced Glycation Endproducts (the RAGE receptor) and how this interaction drives an innate immune response. The publication is the result of the collaboration between researchers coordinated by Prof. Antonella Viola at the Department of Biomedical Sciences at the University of Padua and researchers from Human Technopole coordinated by Prof. Giuseppe Testa, with the support of the European Institute of Oncology and the University of Milan. The study demonstrates how the RAGE receptor found on the surface of specific human immune cells penetrates them and pathologically alters their function. This study also shows how the involvement of RAGE determines the degree of severity with which COVID-19 can manifest.

The study took data from patients hospitalized for COVID-19 during the first phase of the pandemic at the Complex Operative Unit for Infectious Diseases and Tropical Diseases in Padua, led by Dr Anna Maria Cattelan. The research team in Padua isolated and characterized the immune cells from the blood of COVID-19 patients at three different time points during and after the infection, i.e. on admission, at discharge and one month after release.

The analysis then continued in Milan, where researchers used technologies to analyze what happens inside a single cell by looking at the expression of all 20,000 genes encoded by its DNA. The amount of data observed for each patient is comparable to the amount of information in a 140-megapixel image, a resolution at the frontier of the possibilities of commonly available cameras. Images captured over different points of hospitalization amplified the amount of data and provided insight to each patients’ response to the SARS-CoV-2 virus.

The analysis showed that the RAGE receptor induces specific alterations in gene regulation, enhancing the inflammatory effect of the virus and contributing to disease exacerbation. Identifying this new mode of interaction between the virus and human cells is crucial for developing targeted therapeutic strategies, mainly to protect individuals at risk of severe complications, such as the elderly or frail individuals. This discovery could lay the foundations for a more targeted and effective approach to counteracting the spread of the virus in these vulnerable groups. For instance, by comparing the characteristic molecular responses detected in the study with those collected in some global databases, scientists also found that the drug Baricitinib, already approved by AIFA in 2021 for the treatment of COVID-19, could potentially reverse the identified harmful effects.

[summary] => [format] => 2 [safe_value] =>

Published in Cell Press, the study by the University of Padua and Human Technopole, RAGE engagement by SARS-CoV-2 enables monocyte infection and underlies COVID-19 severity identifies how SARS-CoV-2 binds the Receptor for Advanced Glycation Endproducts (the RAGE receptor) and how this interaction drives an innate immune response. The publication is the result of the collaboration between researchers coordinated by Prof. Antonella Viola at the Department of Biomedical Sciences at the University of Padua and researchers from Human Technopole coordinated by Prof. Giuseppe Testa, with the support of the European Institute of Oncology and the University of Milan. The study demonstrates how the RAGE receptor found on the surface of specific human immune cells penetrates them and pathologically alters their function. This study also shows how the involvement of RAGE determines the degree of severity with which COVID-19 can manifest.

The study took data from patients hospitalized for COVID-19 during the first phase of the pandemic at the Complex Operative Unit for Infectious Diseases and Tropical Diseases in Padua, led by Dr Anna Maria Cattelan. The research team in Padua isolated and characterized the immune cells from the blood of COVID-19 patients at three different time points during and after the infection, i.e. on admission, at discharge and one month after release.

The analysis then continued in Milan, where researchers used technologies to analyze what happens inside a single cell by looking at the expression of all 20,000 genes encoded by its DNA. The amount of data observed for each patient is comparable to the amount of information in a 140-megapixel image, a resolution at the frontier of the possibilities of commonly available cameras. Images captured over different points of hospitalization amplified the amount of data and provided insight to each patients’ response to the SARS-CoV-2 virus.

The analysis showed that the RAGE receptor induces specific alterations in gene regulation, enhancing the inflammatory effect of the virus and contributing to disease exacerbation. Identifying this new mode of interaction between the virus and human cells is crucial for developing targeted therapeutic strategies, mainly to protect individuals at risk of severe complications, such as the elderly or frail individuals. This discovery could lay the foundations for a more targeted and effective approach to counteracting the spread of the virus in these vulnerable groups. For instance, by comparing the characteristic molecular responses detected in the study with those collected in some global databases, scientists also found that the drug Baricitinib, already approved by AIFA in 2021 for the treatment of COVID-19, could potentially reverse the identified harmful effects.

[safe_summary] => ) ) [#formatter] => text_summary_or_trimmed [0] => Array ( [#markup] =>

Published in Cell Press, the study by the University of Padua and Human Technopole, RAGE engagement by SARS-CoV-2 enables monocyte infection and underlies COVID-19 severity identifies how SARS-CoV-2 binds the Receptor for Advanced Glycation Endproducts (the RAGE receptor) and how this interaction drives an innate immune response.

) ) [field_img_box_lancio_news] => Array ( [#theme] => field [#weight] => 0 [#title] => Immagine [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_img_box_lancio_news [#field_type] => image [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 441879 [uid] => 2032 [title] => Research identifies a new way in which Covid-19 enters human cells [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 105358 [type] => box_lancio_news [language] => it [created] => 1699879199 [changed] => 1699880483 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1699880483 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Published in Cell Press, the study by the University of Padua and Human Technopole, RAGE engagement by SARS-CoV-2 enables monocyte infection and underlies COVID-19 severity identifies how SARS-CoV-2 binds the Receptor for Advanced Glycation Endproducts (the RAGE receptor) and how this interaction drives an innate immune response. The publication is the result of the collaboration between researchers coordinated by Prof. Antonella Viola at the Department of Biomedical Sciences at the University of Padua and researchers from Human Technopole coordinated by Prof. Giuseppe Testa, with the support of the European Institute of Oncology and the University of Milan. The study demonstrates how the RAGE receptor found on the surface of specific human immune cells penetrates them and pathologically alters their function. This study also shows how the involvement of RAGE determines the degree of severity with which COVID-19 can manifest.

The study took data from patients hospitalized for COVID-19 during the first phase of the pandemic at the Complex Operative Unit for Infectious Diseases and Tropical Diseases in Padua, led by Dr Anna Maria Cattelan. The research team in Padua isolated and characterized the immune cells from the blood of COVID-19 patients at three different time points during and after the infection, i.e. on admission, at discharge and one month after release.

The analysis then continued in Milan, where researchers used technologies to analyze what happens inside a single cell by looking at the expression of all 20,000 genes encoded by its DNA. The amount of data observed for each patient is comparable to the amount of information in a 140-megapixel image, a resolution at the frontier of the possibilities of commonly available cameras. Images captured over different points of hospitalization amplified the amount of data and provided insight to each patients’ response to the SARS-CoV-2 virus.

The analysis showed that the RAGE receptor induces specific alterations in gene regulation, enhancing the inflammatory effect of the virus and contributing to disease exacerbation. Identifying this new mode of interaction between the virus and human cells is crucial for developing targeted therapeutic strategies, mainly to protect individuals at risk of severe complications, such as the elderly or frail individuals. This discovery could lay the foundations for a more targeted and effective approach to counteracting the spread of the virus in these vulnerable groups. For instance, by comparing the characteristic molecular responses detected in the study with those collected in some global databases, scientists also found that the drug Baricitinib, already approved by AIFA in 2021 for the treatment of COVID-19, could potentially reverse the identified harmful effects.

[summary] => [format] => 2 [safe_value] =>

Published in Cell Press, the study by the University of Padua and Human Technopole, RAGE engagement by SARS-CoV-2 enables monocyte infection and underlies COVID-19 severity identifies how SARS-CoV-2 binds the Receptor for Advanced Glycation Endproducts (the RAGE receptor) and how this interaction drives an innate immune response. The publication is the result of the collaboration between researchers coordinated by Prof. Antonella Viola at the Department of Biomedical Sciences at the University of Padua and researchers from Human Technopole coordinated by Prof. Giuseppe Testa, with the support of the European Institute of Oncology and the University of Milan. The study demonstrates how the RAGE receptor found on the surface of specific human immune cells penetrates them and pathologically alters their function. This study also shows how the involvement of RAGE determines the degree of severity with which COVID-19 can manifest.

The study took data from patients hospitalized for COVID-19 during the first phase of the pandemic at the Complex Operative Unit for Infectious Diseases and Tropical Diseases in Padua, led by Dr Anna Maria Cattelan. The research team in Padua isolated and characterized the immune cells from the blood of COVID-19 patients at three different time points during and after the infection, i.e. on admission, at discharge and one month after release.

The analysis then continued in Milan, where researchers used technologies to analyze what happens inside a single cell by looking at the expression of all 20,000 genes encoded by its DNA. The amount of data observed for each patient is comparable to the amount of information in a 140-megapixel image, a resolution at the frontier of the possibilities of commonly available cameras. Images captured over different points of hospitalization amplified the amount of data and provided insight to each patients’ response to the SARS-CoV-2 virus.

The analysis showed that the RAGE receptor induces specific alterations in gene regulation, enhancing the inflammatory effect of the virus and contributing to disease exacerbation. Identifying this new mode of interaction between the virus and human cells is crucial for developing targeted therapeutic strategies, mainly to protect individuals at risk of severe complications, such as the elderly or frail individuals. This discovery could lay the foundations for a more targeted and effective approach to counteracting the spread of the virus in these vulnerable groups. For instance, by comparing the characteristic molecular responses detected in the study with those collected in some global databases, scientists also found that the drug Baricitinib, already approved by AIFA in 2021 for the treatment of COVID-19, could potentially reverse the identified harmful effects.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-11-13T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 124758 [uid] => 2032 [filename] => n_covid_mascherinadonna_2.jpg [uri] => public://n_covid_mascherinadonna_2_0.jpg [filemime] => image/jpeg [filesize] => 17377 [status] => 1 [timestamp] => 1699879199 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => mask [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => A new study by the University of Padua and Human Technopole identifies how SARS-CoV-2 binds the Receptor for Advanced Glycation Endproducts (the RAGE receptor) and how this interaction drives an innate immune response [format] => [safe_value] => A new study by the University of Padua and Human Technopole identifies how SARS-CoV-2 binds the Receptor for Advanced Glycation Endproducts (the RAGE receptor) and how this interaction drives an innate immune response ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-11-13T00:00:00 [value2] => 2024-11-13T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 0 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 3 [current_revision_id] => 441879 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 124758 [uid] => 2032 [filename] => n_covid_mascherinadonna_2.jpg [uri] => public://n_covid_mascherinadonna_2_0.jpg [filemime] => image/jpeg [filesize] => 17377 [status] => 1 [timestamp] => 1699879199 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => mask [title] => ) ) [#formatter] => image [0] => Array ( [#theme] => image_formatter [#item] => Array ( [fid] => 124758 [uid] => 2032 [filename] => n_covid_mascherinadonna_2.jpg [uri] => public://n_covid_mascherinadonna_2_0.jpg [filemime] => image/jpeg [filesize] => 17377 [status] => 1 [timestamp] => 1699879199 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => mask [title] => ) [#image_style] => [#path] => ) ) [field_abstract_news] => Array ( [#theme] => field [#weight] => 0 [#title] => Abstract [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_abstract_news [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 441879 [uid] => 2032 [title] => Research identifies a new way in which Covid-19 enters human cells [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 105358 [type] => box_lancio_news [language] => it [created] => 1699879199 [changed] => 1699880483 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1699880483 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Published in Cell Press, the study by the University of Padua and Human Technopole, RAGE engagement by SARS-CoV-2 enables monocyte infection and underlies COVID-19 severity identifies how SARS-CoV-2 binds the Receptor for Advanced Glycation Endproducts (the RAGE receptor) and how this interaction drives an innate immune response. The publication is the result of the collaboration between researchers coordinated by Prof. Antonella Viola at the Department of Biomedical Sciences at the University of Padua and researchers from Human Technopole coordinated by Prof. Giuseppe Testa, with the support of the European Institute of Oncology and the University of Milan. The study demonstrates how the RAGE receptor found on the surface of specific human immune cells penetrates them and pathologically alters their function. This study also shows how the involvement of RAGE determines the degree of severity with which COVID-19 can manifest.

The study took data from patients hospitalized for COVID-19 during the first phase of the pandemic at the Complex Operative Unit for Infectious Diseases and Tropical Diseases in Padua, led by Dr Anna Maria Cattelan. The research team in Padua isolated and characterized the immune cells from the blood of COVID-19 patients at three different time points during and after the infection, i.e. on admission, at discharge and one month after release.

The analysis then continued in Milan, where researchers used technologies to analyze what happens inside a single cell by looking at the expression of all 20,000 genes encoded by its DNA. The amount of data observed for each patient is comparable to the amount of information in a 140-megapixel image, a resolution at the frontier of the possibilities of commonly available cameras. Images captured over different points of hospitalization amplified the amount of data and provided insight to each patients’ response to the SARS-CoV-2 virus.

The analysis showed that the RAGE receptor induces specific alterations in gene regulation, enhancing the inflammatory effect of the virus and contributing to disease exacerbation. Identifying this new mode of interaction between the virus and human cells is crucial for developing targeted therapeutic strategies, mainly to protect individuals at risk of severe complications, such as the elderly or frail individuals. This discovery could lay the foundations for a more targeted and effective approach to counteracting the spread of the virus in these vulnerable groups. For instance, by comparing the characteristic molecular responses detected in the study with those collected in some global databases, scientists also found that the drug Baricitinib, already approved by AIFA in 2021 for the treatment of COVID-19, could potentially reverse the identified harmful effects.

[summary] => [format] => 2 [safe_value] =>

Published in Cell Press, the study by the University of Padua and Human Technopole, RAGE engagement by SARS-CoV-2 enables monocyte infection and underlies COVID-19 severity identifies how SARS-CoV-2 binds the Receptor for Advanced Glycation Endproducts (the RAGE receptor) and how this interaction drives an innate immune response. The publication is the result of the collaboration between researchers coordinated by Prof. Antonella Viola at the Department of Biomedical Sciences at the University of Padua and researchers from Human Technopole coordinated by Prof. Giuseppe Testa, with the support of the European Institute of Oncology and the University of Milan. The study demonstrates how the RAGE receptor found on the surface of specific human immune cells penetrates them and pathologically alters their function. This study also shows how the involvement of RAGE determines the degree of severity with which COVID-19 can manifest.

The study took data from patients hospitalized for COVID-19 during the first phase of the pandemic at the Complex Operative Unit for Infectious Diseases and Tropical Diseases in Padua, led by Dr Anna Maria Cattelan. The research team in Padua isolated and characterized the immune cells from the blood of COVID-19 patients at three different time points during and after the infection, i.e. on admission, at discharge and one month after release.

The analysis then continued in Milan, where researchers used technologies to analyze what happens inside a single cell by looking at the expression of all 20,000 genes encoded by its DNA. The amount of data observed for each patient is comparable to the amount of information in a 140-megapixel image, a resolution at the frontier of the possibilities of commonly available cameras. Images captured over different points of hospitalization amplified the amount of data and provided insight to each patients’ response to the SARS-CoV-2 virus.

The analysis showed that the RAGE receptor induces specific alterations in gene regulation, enhancing the inflammatory effect of the virus and contributing to disease exacerbation. Identifying this new mode of interaction between the virus and human cells is crucial for developing targeted therapeutic strategies, mainly to protect individuals at risk of severe complications, such as the elderly or frail individuals. This discovery could lay the foundations for a more targeted and effective approach to counteracting the spread of the virus in these vulnerable groups. For instance, by comparing the characteristic molecular responses detected in the study with those collected in some global databases, scientists also found that the drug Baricitinib, already approved by AIFA in 2021 for the treatment of COVID-19, could potentially reverse the identified harmful effects.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-11-13T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 124758 [uid] => 2032 [filename] => n_covid_mascherinadonna_2.jpg [uri] => public://n_covid_mascherinadonna_2_0.jpg [filemime] => image/jpeg [filesize] => 17377 [status] => 1 [timestamp] => 1699879199 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => mask [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => A new study by the University of Padua and Human Technopole identifies how SARS-CoV-2 binds the Receptor for Advanced Glycation Endproducts (the RAGE receptor) and how this interaction drives an innate immune response [format] => [safe_value] => A new study by the University of Padua and Human Technopole identifies how SARS-CoV-2 binds the Receptor for Advanced Glycation Endproducts (the RAGE receptor) and how this interaction drives an innate immune response ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-11-13T00:00:00 [value2] => 2024-11-13T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 0 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 3 [current_revision_id] => 441879 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => A new study by the University of Padua and Human Technopole identifies how SARS-CoV-2 binds the Receptor for Advanced Glycation Endproducts (the RAGE receptor) and how this interaction drives an innate immune response [format] => [safe_value] => A new study by the University of Padua and Human Technopole identifies how SARS-CoV-2 binds the Receptor for Advanced Glycation Endproducts (the RAGE receptor) and how this interaction drives an innate immune response ) ) [#formatter] => text_default [0] => Array ( [#markup] => A new study by the University of Padua and Human Technopole identifies how SARS-CoV-2 binds the Receptor for Advanced Glycation Endproducts (the RAGE receptor) and how this interaction drives an innate immune response ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about Research identifies a new way in which Covid-19 enters human cells [href] => node/105358 [html] => 1 [attributes] => Array ( [rel] => tag [title] => Research identifies a new way in which Covid-19 enters human cells ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) [field_date_box_lancio_news] => Array ( [#theme] => field [#weight] => 1 [#title] => Data [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_date_box_lancio_news [#field_type] => date [#field_translatable] => 0 [#entity_type] => node [#bundle] => box_lancio_news [#object] => stdClass Object ( [vid] => 441879 [uid] => 2032 [title] => Research identifies a new way in which Covid-19 enters human cells [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 105358 [type] => box_lancio_news [language] => it [created] => 1699879199 [changed] => 1699880483 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1699880483 [revision_uid] => 2032 [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

Published in Cell Press, the study by the University of Padua and Human Technopole, RAGE engagement by SARS-CoV-2 enables monocyte infection and underlies COVID-19 severity identifies how SARS-CoV-2 binds the Receptor for Advanced Glycation Endproducts (the RAGE receptor) and how this interaction drives an innate immune response. The publication is the result of the collaboration between researchers coordinated by Prof. Antonella Viola at the Department of Biomedical Sciences at the University of Padua and researchers from Human Technopole coordinated by Prof. Giuseppe Testa, with the support of the European Institute of Oncology and the University of Milan. The study demonstrates how the RAGE receptor found on the surface of specific human immune cells penetrates them and pathologically alters their function. This study also shows how the involvement of RAGE determines the degree of severity with which COVID-19 can manifest.

The study took data from patients hospitalized for COVID-19 during the first phase of the pandemic at the Complex Operative Unit for Infectious Diseases and Tropical Diseases in Padua, led by Dr Anna Maria Cattelan. The research team in Padua isolated and characterized the immune cells from the blood of COVID-19 patients at three different time points during and after the infection, i.e. on admission, at discharge and one month after release.

The analysis then continued in Milan, where researchers used technologies to analyze what happens inside a single cell by looking at the expression of all 20,000 genes encoded by its DNA. The amount of data observed for each patient is comparable to the amount of information in a 140-megapixel image, a resolution at the frontier of the possibilities of commonly available cameras. Images captured over different points of hospitalization amplified the amount of data and provided insight to each patients’ response to the SARS-CoV-2 virus.

The analysis showed that the RAGE receptor induces specific alterations in gene regulation, enhancing the inflammatory effect of the virus and contributing to disease exacerbation. Identifying this new mode of interaction between the virus and human cells is crucial for developing targeted therapeutic strategies, mainly to protect individuals at risk of severe complications, such as the elderly or frail individuals. This discovery could lay the foundations for a more targeted and effective approach to counteracting the spread of the virus in these vulnerable groups. For instance, by comparing the characteristic molecular responses detected in the study with those collected in some global databases, scientists also found that the drug Baricitinib, already approved by AIFA in 2021 for the treatment of COVID-19, could potentially reverse the identified harmful effects.

[summary] => [format] => 2 [safe_value] =>

Published in Cell Press, the study by the University of Padua and Human Technopole, RAGE engagement by SARS-CoV-2 enables monocyte infection and underlies COVID-19 severity identifies how SARS-CoV-2 binds the Receptor for Advanced Glycation Endproducts (the RAGE receptor) and how this interaction drives an innate immune response. The publication is the result of the collaboration between researchers coordinated by Prof. Antonella Viola at the Department of Biomedical Sciences at the University of Padua and researchers from Human Technopole coordinated by Prof. Giuseppe Testa, with the support of the European Institute of Oncology and the University of Milan. The study demonstrates how the RAGE receptor found on the surface of specific human immune cells penetrates them and pathologically alters their function. This study also shows how the involvement of RAGE determines the degree of severity with which COVID-19 can manifest.

The study took data from patients hospitalized for COVID-19 during the first phase of the pandemic at the Complex Operative Unit for Infectious Diseases and Tropical Diseases in Padua, led by Dr Anna Maria Cattelan. The research team in Padua isolated and characterized the immune cells from the blood of COVID-19 patients at three different time points during and after the infection, i.e. on admission, at discharge and one month after release.

The analysis then continued in Milan, where researchers used technologies to analyze what happens inside a single cell by looking at the expression of all 20,000 genes encoded by its DNA. The amount of data observed for each patient is comparable to the amount of information in a 140-megapixel image, a resolution at the frontier of the possibilities of commonly available cameras. Images captured over different points of hospitalization amplified the amount of data and provided insight to each patients’ response to the SARS-CoV-2 virus.

The analysis showed that the RAGE receptor induces specific alterations in gene regulation, enhancing the inflammatory effect of the virus and contributing to disease exacerbation. Identifying this new mode of interaction between the virus and human cells is crucial for developing targeted therapeutic strategies, mainly to protect individuals at risk of severe complications, such as the elderly or frail individuals. This discovery could lay the foundations for a more targeted and effective approach to counteracting the spread of the virus in these vulnerable groups. For instance, by comparing the characteristic molecular responses detected in the study with those collected in some global databases, scientists also found that the drug Baricitinib, already approved by AIFA in 2021 for the treatment of COVID-19, could potentially reverse the identified harmful effects.

[safe_summary] => ) ) ) [field_date_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-11-13T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_etichetta_box_lancio_news] => Array ( ) [field_img_box_lancio_news] => Array ( [und] => Array ( [0] => Array ( [fid] => 124758 [uid] => 2032 [filename] => n_covid_mascherinadonna_2.jpg [uri] => public://n_covid_mascherinadonna_2_0.jpg [filemime] => image/jpeg [filesize] => 17377 [status] => 1 [timestamp] => 1699879199 [type] => image [field_file_image_alt_text] => Array ( ) [field_file_image_title_text] => Array ( ) [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( [height] => 227 [width] => 677 ) [height] => 227 [width] => 677 [alt] => mask [title] => ) ) ) [field_link_alla_news] => Array ( ) [field_link_esterno_news] => Array ( ) [field_pagina_associata] => Array ( ) [field_link_etichetta] => Array ( ) [field_abstract_news] => Array ( [und] => Array ( [0] => Array ( [value] => A new study by the University of Padua and Human Technopole identifies how SARS-CoV-2 binds the Receptor for Advanced Glycation Endproducts (the RAGE receptor) and how this interaction drives an innate immune response [format] => [safe_value] => A new study by the University of Padua and Human Technopole identifies how SARS-CoV-2 binds the Receptor for Advanced Glycation Endproducts (the RAGE receptor) and how this interaction drives an innate immune response ) ) ) [field_allegato_news] => Array ( ) [field_categorie_news] => Array ( [und] => Array ( [0] => Array ( [tid] => 2296 ) ) ) [field_pub_date] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-11-13T00:00:00 [value2] => 2024-11-13T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) ) [field_layout_news] => Array ( [und] => Array ( [0] => Array ( [value] => single ) ) ) [field_testo_opzionale_news] => Array ( ) [field_url_en_page] => Array ( ) [field_url_en_page_label] => Array ( ) [path] => Array ( [pathauto] => 0 ) [name] => francesca.forzan [picture] => 0 [data] => b:0; [num_revisions] => 3 [current_revision_id] => 441879 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => 2023-11-13T00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => date ) ) [#formatter] => date_default [0] => Array ( [#markup] => Lun, 13/11/2023 ) ) )

RICERCA UNIPD - Human Technopole - UniMi - IEO. COVID-19: SCOPERTA UNA NUOVA CHIAVE CON CUI IL VIRUS ENTRA NELLE CELLULE UMANE

Submitted by stampa on Lun, 13/11/2023 - 13:04
Array ( [field_luogo_area_stampa] => Array ( [#theme] => field [#weight] => -4 [#title] => Luogo [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_luogo_area_stampa [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato_area_stampa [#object] => stdClass Object ( [vid] => 441872 [uid] => 8835 [title] => RICERCA UNIPD - Human Technopole - UniMi - IEO. COVID-19: SCOPERTA UNA NUOVA CHIAVE CON CUI IL VIRUS ENTRA NELLE CELLULE UMANE [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 105357 [type] => allegato_area_stampa [language] => und [created] => 1699877058 [changed] => 1699877376 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1699877376 [revision_uid] => 8835 [body] => Array ( ) [field_allegato_area_stampa] => Array ( [und] => Array ( [0] => Array ( [fid] => 124757 [uid] => 8835 [filename] => RICERCA - Covid 19 Ecco come il virus entra nelle cellule.pdf [uri] => public://RICERCA - Covid 19 Ecco come il virus entra nelle cellule.pdf [filemime] => application/pdf [filesize] => 873179 [status] => 1 [timestamp] => 1699877058 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [field_all_imm_area_stampa] => Array ( ) [field_data_area_stampa] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-11-13 00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => datetime ) ) ) [field_luogo_area_stampa] => Array ( [und] => Array ( [0] => Array ( [value] => Padova [format] => [safe_value] => Padova ) ) ) [name] => stampa [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 441872 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Padova [format] => [safe_value] => Padova ) ) [#formatter] => text_default [0] => Array ( [#markup] => Padova ) ) [field_data_area_stampa] => Array ( [#theme] => field [#weight] => -3 [#title] => Data [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_data_area_stampa [#field_type] => datetime [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato_area_stampa [#object] => stdClass Object ( [vid] => 441872 [uid] => 8835 [title] => RICERCA UNIPD - Human Technopole - UniMi - IEO. COVID-19: SCOPERTA UNA NUOVA CHIAVE CON CUI IL VIRUS ENTRA NELLE CELLULE UMANE [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 105357 [type] => allegato_area_stampa [language] => und [created] => 1699877058 [changed] => 1699877376 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1699877376 [revision_uid] => 8835 [body] => Array ( ) [field_allegato_area_stampa] => Array ( [und] => Array ( [0] => Array ( [fid] => 124757 [uid] => 8835 [filename] => RICERCA - Covid 19 Ecco come il virus entra nelle cellule.pdf [uri] => public://RICERCA - Covid 19 Ecco come il virus entra nelle cellule.pdf [filemime] => application/pdf [filesize] => 873179 [status] => 1 [timestamp] => 1699877058 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [field_all_imm_area_stampa] => Array ( ) [field_data_area_stampa] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-11-13 00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => datetime ) ) ) [field_luogo_area_stampa] => Array ( [und] => Array ( [0] => Array ( [value] => Padova [format] => [safe_value] => Padova ) ) ) [name] => stampa [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 441872 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => 2023-11-13 00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => datetime ) ) [#formatter] => date_default [0] => Array ( [#markup] => Lun, 13/11/2023 ) ) [field_allegato_area_stampa] => Array ( [#theme] => field [#weight] => -2 [#title] => Allegato [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_allegato_area_stampa [#field_type] => file [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato_area_stampa [#object] => stdClass Object ( [vid] => 441872 [uid] => 8835 [title] => RICERCA UNIPD - Human Technopole - UniMi - IEO. COVID-19: SCOPERTA UNA NUOVA CHIAVE CON CUI IL VIRUS ENTRA NELLE CELLULE UMANE [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 105357 [type] => allegato_area_stampa [language] => und [created] => 1699877058 [changed] => 1699877376 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1699877376 [revision_uid] => 8835 [body] => Array ( ) [field_allegato_area_stampa] => Array ( [und] => Array ( [0] => Array ( [fid] => 124757 [uid] => 8835 [filename] => RICERCA - Covid 19 Ecco come il virus entra nelle cellule.pdf [uri] => public://RICERCA - Covid 19 Ecco come il virus entra nelle cellule.pdf [filemime] => application/pdf [filesize] => 873179 [status] => 1 [timestamp] => 1699877058 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [field_all_imm_area_stampa] => Array ( ) [field_data_area_stampa] => Array ( [und] => Array ( [0] => Array ( [value] => 2023-11-13 00:00:00 [timezone] => Europe/Paris [timezone_db] => Europe/Paris [date_type] => datetime ) ) ) [field_luogo_area_stampa] => Array ( [und] => Array ( [0] => Array ( [value] => Padova [format] => [safe_value] => Padova ) ) ) [name] => stampa [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 441872 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 124757 [uid] => 8835 [filename] => RICERCA - Covid 19 Ecco come il virus entra nelle cellule.pdf [uri] => public://RICERCA - Covid 19 Ecco come il virus entra nelle cellule.pdf [filemime] => application/pdf [filesize] => 873179 [status] => 1 [timestamp] => 1699877058 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) [#formatter] => file_default [0] => Array ( [#theme] => file_link [#file] => stdClass Object ( [fid] => 124757 [uid] => 8835 [filename] => RICERCA - Covid 19 Ecco come il virus entra nelle cellule.pdf [uri] => public://RICERCA - Covid 19 Ecco come il virus entra nelle cellule.pdf [filemime] => application/pdf [filesize] => 873179 [status] => 1 [timestamp] => 1699877058 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2048 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about RICERCA UNIPD - Human Technopole - UniMi - IEO. COVID-19: SCOPERTA UNA NUOVA CHIAVE CON CUI IL VIRUS ENTRA NELLE CELLULE UMANE [href] => node/105357 [html] => 1 [attributes] => Array ( [rel] => tag [title] => RICERCA UNIPD - Human Technopole - UniMi - IEO. COVID-19: SCOPERTA UNA NUOVA CHIAVE CON CUI IL VIRUS ENTRA NELLE CELLULE UMANE ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

2023S36 - Esito prova scritta - candidati ammessi al colloquio

Submitted by stefano.zampieri on Lun, 13/11/2023 - 12:03
Array ( [field_titolo_frontend_all] => Array ( [#theme] => field [#weight] => -4 [#title] => Titolo frontend [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_titolo_frontend_all [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 441856 [uid] => 32 [title] => 2023S36 - Esito prova scritta - candidati ammessi al colloquio [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 105356 [type] => allegato [language] => it [created] => 1699873402 [changed] => 1699952489 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1699952489 [revision_uid] => 32 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

link accesso agli atti prova scritta

[summary] => [format] => 2 [safe_value] =>

link accesso agli atti prova scritta

[safe_summary] => ) ) ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Esito prova scritta - candidati ammessi al colloquio [format] => [safe_value] => Esito prova scritta - candidati ammessi al colloquio ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 124755 [uid] => 32 [filename] => 20 esito prova scritta 2023S36.pdf [uri] => public://2023/20 esito prova scritta 2023S36.pdf [filemime] => application/pdf [filesize] => 617287 [status] => 1 [timestamp] => 1699873227 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2529 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 441856 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Esito prova scritta - candidati ammessi al colloquio [format] => [safe_value] => Esito prova scritta - candidati ammessi al colloquio ) ) [#formatter] => text_default [0] => Array ( [#markup] => Esito prova scritta - candidati ammessi al colloquio ) ) [field_allegato_file] => Array ( [#theme] => field [#weight] => -3 [#title] => File [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_allegato_file [#field_type] => file [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 441856 [uid] => 32 [title] => 2023S36 - Esito prova scritta - candidati ammessi al colloquio [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 105356 [type] => allegato [language] => it [created] => 1699873402 [changed] => 1699952489 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1699952489 [revision_uid] => 32 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

link accesso agli atti prova scritta

[summary] => [format] => 2 [safe_value] =>

link accesso agli atti prova scritta

[safe_summary] => ) ) ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Esito prova scritta - candidati ammessi al colloquio [format] => [safe_value] => Esito prova scritta - candidati ammessi al colloquio ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 124755 [uid] => 32 [filename] => 20 esito prova scritta 2023S36.pdf [uri] => public://2023/20 esito prova scritta 2023S36.pdf [filemime] => application/pdf [filesize] => 617287 [status] => 1 [timestamp] => 1699873227 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2529 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 441856 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 124755 [uid] => 32 [filename] => 20 esito prova scritta 2023S36.pdf [uri] => public://2023/20 esito prova scritta 2023S36.pdf [filemime] => application/pdf [filesize] => 617287 [status] => 1 [timestamp] => 1699873227 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2529 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) [#formatter] => file_default [0] => Array ( [#theme] => file_link [#file] => stdClass Object ( [fid] => 124755 [uid] => 32 [filename] => 20 esito prova scritta 2023S36.pdf [uri] => public://2023/20 esito prova scritta 2023S36.pdf [filemime] => application/pdf [filesize] => 617287 [status] => 1 [timestamp] => 1699873227 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2529 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [body] => Array ( [#theme] => field [#weight] => -1 [#title] => Body [#access] => 1 [#label_display] => hidden [#view_mode] => teaser [#language] => und [#field_name] => body [#field_type] => text_with_summary [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 441856 [uid] => 32 [title] => 2023S36 - Esito prova scritta - candidati ammessi al colloquio [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 105356 [type] => allegato [language] => it [created] => 1699873402 [changed] => 1699952489 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1699952489 [revision_uid] => 32 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( [und] => Array ( [0] => Array ( [value] =>

link accesso agli atti prova scritta

[summary] => [format] => 2 [safe_value] =>

link accesso agli atti prova scritta

[safe_summary] => ) ) ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Esito prova scritta - candidati ammessi al colloquio [format] => [safe_value] => Esito prova scritta - candidati ammessi al colloquio ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 124755 [uid] => 32 [filename] => 20 esito prova scritta 2023S36.pdf [uri] => public://2023/20 esito prova scritta 2023S36.pdf [filemime] => application/pdf [filesize] => 617287 [status] => 1 [timestamp] => 1699873227 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2529 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => stefano.zampieri [picture] => 0 [data] => a:2:{s:13:"form_build_id";s:48:"form-WsCySmos4vAVlyFhG6gU5T7knfAyqco8LxlocSU_yIA";s:14:"wysiwyg_status";a:1:{i:1;i:1;}} [num_revisions] => 1 [current_revision_id] => 441856 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] =>

link accesso agli atti prova scritta

[summary] => [format] => 2 [safe_value] =>

link accesso agli atti prova scritta

[safe_summary] => ) ) [#formatter] => text_summary_or_trimmed [0] => Array ( [#markup] =>

link accesso agli atti prova scritta

) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about 2023S36 - Esito prova scritta - candidati ammessi al colloquio [href] => node/105356 [html] => 1 [attributes] => Array ( [rel] => tag [title] => 2023S36 - Esito prova scritta - candidati ammessi al colloquio ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

2023RUB06 - Allegato 14 - Verbale 1 - Criteri

Submitted by carriere.docenti on Lun, 13/11/2023 - 11:46
Array ( [field_titolo_frontend_all] => Array ( [#theme] => field [#weight] => -4 [#title] => Titolo frontend [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_titolo_frontend_all [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 441850 [uid] => 8831 [title] => 2023RUB06 - Allegato 14 - Verbale 1 - Criteri [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 105355 [type] => allegato [language] => it [created] => 1699872410 [changed] => 1699952384 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1699952384 [revision_uid] => 102 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Verbale 1 - Criteri [format] => [safe_value] => Verbale 1 - Criteri ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 124753 [uid] => 32 [filename] => Verbale 1 CRITERI - 2023RUB06 All.14 ING-INF 04.pdf.pdf [uri] => public://2023/Verbale 1 CRITERI - 2023RUB06 All.14 ING-INF 04.pdf.pdf [filemime] => application/pdf [filesize] => 284220 [status] => 1 [timestamp] => 1699872406 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2529 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => carriere.docenti [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 441850 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Verbale 1 - Criteri [format] => [safe_value] => Verbale 1 - Criteri ) ) [#formatter] => text_default [0] => Array ( [#markup] => Verbale 1 - Criteri ) ) [field_allegato_file] => Array ( [#theme] => field [#weight] => -3 [#title] => File [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_allegato_file [#field_type] => file [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 441850 [uid] => 8831 [title] => 2023RUB06 - Allegato 14 - Verbale 1 - Criteri [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 105355 [type] => allegato [language] => it [created] => 1699872410 [changed] => 1699952384 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1699952384 [revision_uid] => 102 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Verbale 1 - Criteri [format] => [safe_value] => Verbale 1 - Criteri ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 124753 [uid] => 32 [filename] => Verbale 1 CRITERI - 2023RUB06 All.14 ING-INF 04.pdf.pdf [uri] => public://2023/Verbale 1 CRITERI - 2023RUB06 All.14 ING-INF 04.pdf.pdf [filemime] => application/pdf [filesize] => 284220 [status] => 1 [timestamp] => 1699872406 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2529 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => carriere.docenti [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 441850 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 124753 [uid] => 32 [filename] => Verbale 1 CRITERI - 2023RUB06 All.14 ING-INF 04.pdf.pdf [uri] => public://2023/Verbale 1 CRITERI - 2023RUB06 All.14 ING-INF 04.pdf.pdf [filemime] => application/pdf [filesize] => 284220 [status] => 1 [timestamp] => 1699872406 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2529 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) [#formatter] => file_default [0] => Array ( [#theme] => file_link [#file] => stdClass Object ( [fid] => 124753 [uid] => 32 [filename] => Verbale 1 CRITERI - 2023RUB06 All.14 ING-INF 04.pdf.pdf [uri] => public://2023/Verbale 1 CRITERI - 2023RUB06 All.14 ING-INF 04.pdf.pdf [filemime] => application/pdf [filesize] => 284220 [status] => 1 [timestamp] => 1699872406 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2529 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about 2023RUB06 - Allegato 14 - Verbale 1 - Criteri [href] => node/105355 [html] => 1 [attributes] => Array ( [rel] => tag [title] => 2023RUB06 - Allegato 14 - Verbale 1 - Criteri ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

Decreto presidenziale Pubblicazione in esecuzione TAR Lazio - Roma, pubblicato il 07.11.2023, n. 7380, r.g. 14540/2023

Submitted by simonetta.admin on Lun, 13/11/2023 - 11:39
Array ( [field_titolo_frontend_all] => Array ( [#theme] => field [#weight] => -4 [#title] => Titolo frontend [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_titolo_frontend_all [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 441843 [uid] => 102 [title] => Decreto presidenziale Pubblicazione in esecuzione TAR Lazio - Roma, pubblicato il 07.11.2023, n. 7380, r.g. 14540/2023 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 105351 [type] => allegato [language] => it [created] => 1699871952 [changed] => 1699872077 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1699872077 [revision_uid] => 102 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Decreto presidenziale [format] => [safe_value] => Decreto presidenziale ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 124751 [uid] => 102 [filename] => 3. decreto presidenziale Tar Lazio 7380 2023.pdf [uri] => public://2023/3. decreto presidenziale Tar Lazio 7380 2023.pdf [filemime] => application/pdf [filesize] => 105732 [status] => 1 [timestamp] => 1699872067 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2529 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => simonetta.admin [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 441843 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Decreto presidenziale [format] => [safe_value] => Decreto presidenziale ) ) [#formatter] => text_default [0] => Array ( [#markup] => Decreto presidenziale ) ) [field_allegato_file] => Array ( [#theme] => field [#weight] => -3 [#title] => File [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_allegato_file [#field_type] => file [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 441843 [uid] => 102 [title] => Decreto presidenziale Pubblicazione in esecuzione TAR Lazio - Roma, pubblicato il 07.11.2023, n. 7380, r.g. 14540/2023 [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 105351 [type] => allegato [language] => it [created] => 1699871952 [changed] => 1699872077 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1699872077 [revision_uid] => 102 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Decreto presidenziale [format] => [safe_value] => Decreto presidenziale ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 124751 [uid] => 102 [filename] => 3. decreto presidenziale Tar Lazio 7380 2023.pdf [uri] => public://2023/3. decreto presidenziale Tar Lazio 7380 2023.pdf [filemime] => application/pdf [filesize] => 105732 [status] => 1 [timestamp] => 1699872067 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2529 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => simonetta.admin [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 441843 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 124751 [uid] => 102 [filename] => 3. decreto presidenziale Tar Lazio 7380 2023.pdf [uri] => public://2023/3. decreto presidenziale Tar Lazio 7380 2023.pdf [filemime] => application/pdf [filesize] => 105732 [status] => 1 [timestamp] => 1699872067 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2529 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) [#formatter] => file_default [0] => Array ( [#theme] => file_link [#file] => stdClass Object ( [fid] => 124751 [uid] => 102 [filename] => 3. decreto presidenziale Tar Lazio 7380 2023.pdf [uri] => public://2023/3. decreto presidenziale Tar Lazio 7380 2023.pdf [filemime] => application/pdf [filesize] => 105732 [status] => 1 [timestamp] => 1699872067 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2529 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about Decreto presidenziale Pubblicazione in esecuzione TAR Lazio - Roma, pubblicato il 07.11.2023, n. 7380, r.g. 14540/2023 [href] => node/105351 [html] => 1 [attributes] => Array ( [rel] => tag [title] => Decreto presidenziale Pubblicazione in esecuzione TAR Lazio - Roma, pubblicato il 07.11.2023, n. 7380, r.g. 14540/2023 ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

Nota Pubblicazione in esecuzione TAR Lazio - Roma - vari

Submitted by simonetta.admin on Lun, 13/11/2023 - 11:37
Array ( [field_titolo_frontend_all] => Array ( [#theme] => field [#weight] => -4 [#title] => Titolo frontend [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_titolo_frontend_all [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 441844 [uid] => 102 [title] => Nota Pubblicazione in esecuzione TAR Lazio - Roma - vari [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 105352 [type] => allegato [language] => it [created] => 1699871845 [changed] => 1700216448 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1700216448 [revision_uid] => 4 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] =>

Lo svolgimento del processo può essere seguito sul sito www.giustizia-amministrativa.it dalle parti attraverso le modalità rese note sul sito medesimo.



[format] => [safe_value] => <p><em>Lo svolgimento del processo può essere seguito sul sito&nbsp;<a href="http://www.giustizia-amministrativa.it/">www.giustizia-amministrativa.it</a>&nbsp;dalle parti attraverso le modalità rese note sul sito medesimo.</em></p><br><br> ) ) ) [field_allegato_file] => Array ( ) [name] => simonetta.admin [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 441844 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] =>

Lo svolgimento del processo può essere seguito sul sito www.giustizia-amministrativa.it dalle parti attraverso le modalità rese note sul sito medesimo.



[format] => [safe_value] => <p><em>Lo svolgimento del processo può essere seguito sul sito&nbsp;<a href="http://www.giustizia-amministrativa.it/">www.giustizia-amministrativa.it</a>&nbsp;dalle parti attraverso le modalità rese note sul sito medesimo.</em></p><br><br> ) ) [#formatter] => text_default [0] => Array ( [#markup] => <p><em>Lo svolgimento del processo può essere seguito sul sito&nbsp;<a href="http://www.giustizia-amministrativa.it/">www.giustizia-amministrativa.it</a>&nbsp;dalle parti attraverso le modalità rese note sul sito medesimo.</em></p><br><br> ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about Nota Pubblicazione in esecuzione TAR Lazio - Roma - vari [href] => node/105352 [html] => 1 [attributes] => Array ( [rel] => tag [title] => Nota Pubblicazione in esecuzione TAR Lazio - Roma - vari ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

2023RUA05 Allegato 9 - Decreto di costituzione della commissione-

Submitted by carriere.docenti on Lun, 13/11/2023 - 11:14
Array ( [field_titolo_frontend_all] => Array ( [#theme] => field [#weight] => -4 [#title] => Titolo frontend [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_titolo_frontend_all [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 441838 [uid] => 8831 [title] => 2023RUA05 Allegato 9 - Decreto di costituzione della commissione- [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 105350 [type] => allegato [language] => it [created] => 1699870465 [changed] => 1699952238 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1699952238 [revision_uid] => 102 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Decreto di costituzione della commissione [format] => [safe_value] => Decreto di costituzione della commissione ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 124745 [uid] => 32 [filename] => DR nomina commissione MED11 secondo bando.pdf [uri] => public://2023/DR nomina commissione MED11 secondo bando.pdf [filemime] => application/pdf [filesize] => 148854 [status] => 1 [timestamp] => 1699870291 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2529 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => carriere.docenti [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 441838 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Decreto di costituzione della commissione [format] => [safe_value] => Decreto di costituzione della commissione ) ) [#formatter] => text_default [0] => Array ( [#markup] => Decreto di costituzione della commissione ) ) [field_allegato_file] => Array ( [#theme] => field [#weight] => -3 [#title] => File [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_allegato_file [#field_type] => file [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 441838 [uid] => 8831 [title] => 2023RUA05 Allegato 9 - Decreto di costituzione della commissione- [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 105350 [type] => allegato [language] => it [created] => 1699870465 [changed] => 1699952238 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1699952238 [revision_uid] => 102 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Decreto di costituzione della commissione [format] => [safe_value] => Decreto di costituzione della commissione ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 124745 [uid] => 32 [filename] => DR nomina commissione MED11 secondo bando.pdf [uri] => public://2023/DR nomina commissione MED11 secondo bando.pdf [filemime] => application/pdf [filesize] => 148854 [status] => 1 [timestamp] => 1699870291 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2529 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => carriere.docenti [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 441838 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 124745 [uid] => 32 [filename] => DR nomina commissione MED11 secondo bando.pdf [uri] => public://2023/DR nomina commissione MED11 secondo bando.pdf [filemime] => application/pdf [filesize] => 148854 [status] => 1 [timestamp] => 1699870291 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2529 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) [#formatter] => file_default [0] => Array ( [#theme] => file_link [#file] => stdClass Object ( [fid] => 124745 [uid] => 32 [filename] => DR nomina commissione MED11 secondo bando.pdf [uri] => public://2023/DR nomina commissione MED11 secondo bando.pdf [filemime] => application/pdf [filesize] => 148854 [status] => 1 [timestamp] => 1699870291 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2529 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about 2023RUA05 Allegato 9 - Decreto di costituzione della commissione- [href] => node/105350 [html] => 1 [attributes] => Array ( [rel] => tag [title] => 2023RUA05 Allegato 9 - Decreto di costituzione della commissione- ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

2023RUA05 Allegato 2- Decreto di costituzione della commissione

Submitted by carriere.docenti on Lun, 13/11/2023 - 11:08
Array ( [field_titolo_frontend_all] => Array ( [#theme] => field [#weight] => -4 [#title] => Titolo frontend [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_titolo_frontend_all [#field_type] => text_long [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 441835 [uid] => 8831 [title] => 2023RUA05 Allegato 2- Decreto di costituzione della commissione [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 105349 [type] => allegato [language] => it [created] => 1699870117 [changed] => 1699952405 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1699952405 [revision_uid] => 102 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Decreto di costituzione della commissione [format] => [safe_value] => Decreto di costituzione della commissione ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 124743 [uid] => 32 [filename] => DR nomina commissione AGR16.pdf [uri] => public://2023/DR nomina commissione AGR16.pdf [filemime] => application/pdf [filesize] => 149193 [status] => 1 [timestamp] => 1699870282 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2529 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => carriere.docenti [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 441835 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [value] => Decreto di costituzione della commissione [format] => [safe_value] => Decreto di costituzione della commissione ) ) [#formatter] => text_default [0] => Array ( [#markup] => Decreto di costituzione della commissione ) ) [field_allegato_file] => Array ( [#theme] => field [#weight] => -3 [#title] => File [#access] => 1 [#label_display] => above [#view_mode] => teaser [#language] => und [#field_name] => field_allegato_file [#field_type] => file [#field_translatable] => 0 [#entity_type] => node [#bundle] => allegato [#object] => stdClass Object ( [vid] => 441835 [uid] => 8831 [title] => 2023RUA05 Allegato 2- Decreto di costituzione della commissione [log] => [status] => 1 [comment] => 0 [promote] => 1 [sticky] => 0 [nid] => 105349 [type] => allegato [language] => it [created] => 1699870117 [changed] => 1699952405 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1699952405 [revision_uid] => 102 [taxonomy_vocabulary_2] => Array ( ) [taxonomy_vocabulary_8] => Array ( ) [body] => Array ( ) [field_titolo_frontend_all] => Array ( [und] => Array ( [0] => Array ( [value] => Decreto di costituzione della commissione [format] => [safe_value] => Decreto di costituzione della commissione ) ) ) [field_allegato_file] => Array ( [und] => Array ( [0] => Array ( [fid] => 124743 [uid] => 32 [filename] => DR nomina commissione AGR16.pdf [uri] => public://2023/DR nomina commissione AGR16.pdf [filemime] => application/pdf [filesize] => 149193 [status] => 1 [timestamp] => 1699870282 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2529 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [name] => carriere.docenti [picture] => 0 [data] => b:0; [num_revisions] => 1 [current_revision_id] => 441835 [is_current] => 1 [is_pending] => [revision_moderation] => [entity_view_prepared] => 1 ) [#items] => Array ( [0] => Array ( [fid] => 124743 [uid] => 32 [filename] => DR nomina commissione AGR16.pdf [uri] => public://2023/DR nomina commissione AGR16.pdf [filemime] => application/pdf [filesize] => 149193 [status] => 1 [timestamp] => 1699870282 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2529 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) [#formatter] => file_default [0] => Array ( [#theme] => file_link [#file] => stdClass Object ( [fid] => 124743 [uid] => 32 [filename] => DR nomina commissione AGR16.pdf [uri] => public://2023/DR nomina commissione AGR16.pdf [filemime] => application/pdf [filesize] => 149193 [status] => 1 [timestamp] => 1699870282 [type] => document [field_folder] => Array ( [und] => Array ( [0] => Array ( [tid] => 2529 ) ) ) [metadata] => Array ( ) [display] => 1 [description] => ) ) ) [links] => Array ( [#theme] => links__node [#pre_render] => Array ( [0] => drupal_pre_render_links ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) [node] => Array ( [#theme] => links__node__node [#links] => Array ( [node-readmore] => Array ( [title] => Read more about 2023RUA05 Allegato 2- Decreto di costituzione della commissione [href] => node/105349 [html] => 1 [attributes] => Array ( [rel] => tag [title] => 2023RUA05 Allegato 2- Decreto di costituzione della commissione ) ) ) [#attributes] => Array ( [class] => Array ( [0] => links [1] => inline ) ) ) ) )

Pagine